SCHEMBL23857504

SCHEMBL23857504

Cc1cc(B2OC(C)(C)C(C)(C)O2)c(C)c2c1CC(C(=O)O)(C(=O)O)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23857275 0.85 UCHL1 (0.30)
SCHEMBL30253200 0.85 UCHL1 (0.30)
SCHEMBL23856899 0.72 ALOX5 (0.34)
SCHEMBL12941752 0.69 PKM (0.40)
SCHEMBL12374406 0.67 MAPK1 (0.39)
SCHEMBL16599583 0.67 KDM4E (0.36)
SCHEMBL10059293 0.67 KDM4E (0.35)
SCHEMBL21067052 0.66 JAK2 (0.34)
SCHEMBL23174510 0.64 CYP3A4 (0.34)
SCHEMBL30077918 0.64 CYP3A4 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 EP disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
EP-4126855-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2023-02-08 EP disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 WO disclosed